Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran added to optimized lipid-lowering therapy in adults with hypercholesterolemia
2021-003759-40Phase 4Active
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hypercholesterolemia comparing Inclisiran + optimized lipid-lowering therapy with Placebo + optimized lipid-lowering therapy (2 arms). Primary endpoint: Proportion of participants achieving individual LDL-C target at day 90. Started Dec 2021; status: active.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2021-003759-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003759-40.